AstraZeneca and AgPlus Diagnostics present clinical data from a novel, 10 minute, electrochemical point of care assay system for the measurement of Eosinophil Derived Neurotoxin (EDN) at ERS 2017
AgPlus and AstraZeneca have worked together to develop a novel point of care test (based on AgPlus’ patented electrochemical immunoassay platform technology) for EDN and have reported the results from a successful pilot clinical study at ERS 2017. A copy of the poster is now available here: ERS 2017 AgAZ poster.
Increased blood eosinophils (EOS) are associated with increased exacerbations, disease severity and mortality in asthma. EDN is an alternative biomarker of eosinophilia that may better reflect eosinophil activity than EOS. EDN can be measured by immunoassay but a clinical diagnostic is not available. In this study, a prototype point of care assay system for the detection of EDN was assessed using a 20ul sample of venous blood, capillary blood or plasma from 10 patients recruited on their historical eosinophil levels to represent a wide range.
The key conclusions of the study were:
- EDN was measurable in capillary blood, venous blood and plasma with the novel point-of-care electrochemical immunoassay platform giving a result in under 10 minutes.
- The measured EDN levels were highly correlated to blood eosinophils.
- EDN may be an alternative biomarker of eosinophilic asthma to EOS and is amenable to rapid, point of care diagnostic technology and since EDN release is an active process that can be triggered by inflammatory mediators, EDN may reflect active pathology in eosinophilic asthma better than eosinophil counts.
About AgPlus Diagnostics Ltd:
AgPlus Diagnostics has developed a diagnostic platform technology that delivers the market requirement of a true fully quantitative PoC test for use across a wide range of clinical applications. The technology, developed for OEM Business-to-Business solutions, provides clients with a customised assay system for rapid PoC diagnostics. The platform can be used across multiple applications and sectors where faster diagnostic results will enable users to make critical decisions in minutes.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.